首站-论文投稿智能助手
典型文献
Antibody-drug conjugates in HER2-positive breast cancer
文献摘要:
Antibody-drug conjugates (ADCs) combine the high specificity of monoclonal antibodies with the high anti-tumor activity of small molecular cytotoxic payloads. The anti-tumor activity of ADCs is mainly achieved by the direct blocking of the receptor by monoclonal antibodies, direct action and bystander effect of cytotoxic drugs, and antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. ADCs have been used in adjuvant therapy and rescue treatment of human epidermal receptor 2 (HER2)-positive breast cancer, greatly improving the prognosis of breast cancer patients. Several ongoing clinical trials of ADC for breast cancer and other solid tumors proved the potential of ADCs will provide more promising treatment options for patients with malignant tumors. This review introduces the mechanism and latest clinical progress of ADC drugs approved for HER2-positive breast cancer to guide clinical practice and conduct research.
文献关键词:
Antibody-drug conjugate;HER2-positive;Breast cancer;T-DM1;DS-8201
作者姓名:
Li Lixi;Zhang Di;Liu Binliang;Lv Dan;Zhai Jingtong;Guan Xiuwen;Yi Zongbi;Ma Fei
作者机构:
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
引用格式:
[1]Li Lixi;Zhang Di;Liu Binliang;Lv Dan;Zhai Jingtong;Guan Xiuwen;Yi Zongbi;Ma Fei-.Antibody-drug conjugates in HER2-positive breast cancer)[J].中华医学杂志(英文版),2022(03):261-267
A类:
B类:
Antibody,conjugates,HER2,positive,breast,cancer,ADCs,combine,high,specificity,monoclonal,antibodies,activity,small,molecular,payloads,mainly,achieved,direct,blocking,receptor,action,bystander,effect,drugs,antibody,dependent,cell,mediated,cytotoxicity,complement,have,been,used,adjuvant,therapy,rescue,treatment,human,epidermal,greatly,improving,prognosis,patients,Several,ongoing,clinical,trials,other,solid,tumors,potential,will,provide,more,promising,options,malignant,This,review,introduces,mechanism,latest,progress,approved,guide,practice,conduct,research,Breast,DM1,DS
AB值:
0.534383
相似文献
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。